Dapagliflozin for treating heart failure with reduced ejection fraction was due to pause, however the topic will now continue on the original timelines and will no longer pause.
The timelines are subject to staff capacity and the ongoing management of the COVID-19 situation and we will continue to review our plans and update our stakeholders accordingly.